Table 2.

Signalment, echocardiographic, and treatment data from 34 dogs undergoing analysis of equilibrium concentrations of renin angiotensin aldosterone system angiotensin peptides. Data shown as mean (SD) or median (interquartile range) unless otherwise specified. See text for description of the modified clinical staging system

	Healthy	Stage B1	Stage B2	Stage C	P
N	8	8	9	9
Sex (F/M)	3/5	3/5	2/7	3/6	.89
Age (years)	8.7 (2.9)	10.8 (1.6)	9.6 (1.7)	9.6 (3.7)	.47
Body weight (kg)	20.0 (9.1‐30.5)	7.5 (4.1‐10.8)	8.4 (6.1‐10.3)	9.4 (8.1‐32.0)	.17
LVIDdN		1.47 (0.10)	1.91 (0.24)	2.14 (0.36)	<.0001
					B1 versus C, P < .0001
					B2 versus C, P = .005
LVIDsN		0.77 (0.64‐0.90)	0.99 (0.96‐1.01)	1.14 (0.94‐1.70)	.21
IVSdN		0.40 (0.07)	0.45 (0.04)	0.45 (0.08)	.23
LVPWdN		0.40 (0.36‐0.43)	0.42 (0.41‐44)	0.44 (0.42‐0.46)	.13
LADN		1.09 (0.96‐1.15)	1.21 (1.13‐1.38)	1.62 (1.50‐1.71)	.003
					B1 versus C, P = .002
AoDN		0.73 (0.66‐0.81)	0.70 (0.69‐0.75)	0.69 (0.63‐0.76)	.75
LA:Ao		1.43 (0.25)	1.83 (0.18)	2.37 (0.57)	.0002
					B1 versus C, P < .0001
					B2 versus C, P = .02
Furosemide (Y/N)		0/8	0/9	9/0
ACEI (Y/N)		0/8	0/9	9/0
Pimobendan (Y/N)		0/8	5/4	9/0
Spironolactone (Y/N)		0/8	0/9	8/1
Other medications				Sildenafil (n, 1)
				Hydrocodone (n, 2)
				Hydrochlorothiazide (n, 1)
				Diltiazem (n, 1)

Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; AoDN, normalized aortic root diameter; IVSdN, normalized interventricular septum thickness at end‐diastole; LA:Ao, left atrium to aortic root diameter ratio; LADN, normalized left atrial diameter; LVIDdN, normalized left ventricular internal diameter at end‐diastole; LVIDsN, normalized left ventricular internal diameter at end‐systole; LVPWdN, normalized left ventricular posterior wall thickness at end‐diastole.